Drug nanocrystals in the commercial pharmaceutical development process

International Journal of Pharmaceutics

Volumn 453, Issue 1, 2013, Pages 142-156

  Möschwitzer, Jan P ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Dissolution rate limited; Drug nanocrystals; High pressure homogenization; Nanosuspension; Wet ball milling

Indexed keywords

COSMETIC; NANOCRYSTAL; POLYSTYRENE; SOLID LIPID NANOPARTICLE; SOLVENT;

CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; COSMETIC INDUSTRY; CRYSTALLIZATION; DECISION TREE; DIFFUSION COEFFICIENT; DISSOLUTION; DOWNSTREAM PROCESSING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG SOLUBILITY; FOOD INDUSTRY; FREEZE DRYING; HIGH PRESSURE HOMOGENIZATION; NONHUMAN; PARTICLE SIZE; PHARMACOLOGICAL PROCEDURES; PLASTIC BOTTLE; PRECIPITATION; PRIORITY JOURNAL; REDUCTION; REVIEW; SOLUBILIZATION; SUSPENSION; WET BALL MILLING;

EID: 84884138452     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.09.034     Document Type: Review

References (162)

1. Al Shaal, L., Müller, R.H., Keck, C.M., 2010. Preserving hesperetin nanosuspensions for dermal application. Pharmazie 65, 86-92.
2. Ali, H.S., York, P., Ali, A.M., Blagden, N., 2011. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J. Control. Release 149, 175-181.
3. Amidon, G.L., Lennernäs, H., Shah, V.P., Crison, J.R., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420.
4. Baert, L., van't Klooster, G., Dries, W., Francois, M., Wouters, A., Basstanie, E., Iterbeke, K., Stappers, F., Stevens, P., Schueller, L., Van Remoortere, P., Kraus, G., Wigerinck, P., Rosier, J., 2009. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 72, 502-508.
5. Basa, S., Muniyappan, T., Karatgi, P., Prabhu, R., Pillai, R., 2008. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev. Ind. Pharm. 34, 1209-1218.
6. Beirowski, J., Inghelbrecht, S., Arien, A., Gieseler, H., 2011. Freeze-drying of nanosuspensions, 1: freezing rate versus formulation design as critical factors to preserve the original particle size distribution. J. Pharm. Sci. 100, 1958-1968.
7. Branchu, S., Rogueda, P.G., Plumb, A.P., Cook, W.G., 2007. A decision-support tool for the formulation of orally active, poorly soluble compounds. Eur. J. Pharm. Sci. 32, 128-139. (Pubitemid 47299301)
8. Brandl, M., Bachmann, D., Drechsler, M., Bauer, K.H., 1990. Liposome preparation by a new high pressure homogenizer gaulin micron Lab 40. Drug Dev. Ind. Pharm. 16, 2167-2191. (Pubitemid 20303064)
9. Breitenbach, J., 2002. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 54, 107-117. (Pubitemid 34919382)
10. Brewster, M.E., Loftsson, T., 2007. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59, 645-666. (Pubitemid 47299263)
11. Brouwers, J., Brewster, M.E., Augustijns, P., 2009. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. 98, 2549-2572.
12. Bruno, J.A.D., Brian, D., Gustow, E., Illig, K.J., Rajagopalan, N., Sarpotdar, P., 1992. Method of Grinding Pharmaceutical Substances. Nano Systems L.L.C., USA.
13. Butler, J.M., Dressman, J.B., 2010. The developability classification system: application of biopharmaceutics concepts to formulation development. J. Pharm. Sci. 99, 4940-4954.
14. Byrappa, K., Ohara, S., Adschiri, T., 2008. Nanoparticles synthesis using supercritical fluid technology - towards biomedical applications. Adv. Drug Deliv. Rev. 60, 299-327.
15. Cerdeira, A.M., Mazzotti, M., Gander, B., 2010. Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability. Int. J. Pharm. 396, 210-218.
16. Chan, H.K., Kwok, P.C., 2011. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 63, 406-416.
17. Chaubal, M.V., 2004. Application of drug delivery technologies in lead candidate selection and optimization. Drug Discov. Today 9, 603-609. (Pubitemid 38900510)
18. Chaubal, M.V., Popescu, C., 2008. Conversion of nanosuspensions into dry powders by spray drying: a case study. Pharm. Res. 25, 2302-2308.
19. Chen, X., Young, T.J., Sarkari, M., Williams 3rd, R.O., Johnston, K.P., 2002. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Int. J. Pharm. 242, 3-14.
20. Chiang, P.C., Ran, Y., Chou, K.J., Cui, Y., Wong, H., 2011. Investigation of utilization of nanosuspension formulation to enhance exposure of 1,3-dicyclohexylurea in rats: preparation for PK/PD study via subcutaneous route of nanosuspension drug delivery. Nanoscale Res. Lett. 6, 413.
21. Chiou, H., Li, L., Hu, T., Chan, H.K., Chen, J.F., Yun, J., 2007. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation. Int. J. Pharm. 331, 93-98. (Pubitemid 46176506)
22. Collins-Gold, L.C., Lyons, R.T., Bartholow, L.C., 1990. Parenteral emulsions for drug delivery. Adv. Drug Deliv. Rev. 5, 189-208. (Pubitemid 20333024)
23. Cooper, E.R., 2010. Nanoparticles: a personal experience for formulating poorly water soluble drugs. J. Control. Release 141, 300-302.
24. Crisp, M.T., Tucker, C.J., Rogers, T.L., Williams 3rd, R.O., Johnston, K.P., 2007. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J. Control. Release 117, 351-359. (Pubitemid 46216578)
25. Dai, W.G., Dong, L.C., Song, Y.Q., 2007. Nanosizing of a drug/carrageenan complex to increase solubility and dissolution rate. Int. J. Pharm. 342, 201-207. (Pubitemid 47259320)
26. de Waard, H., Frijlink, H., Hinrichs, W., 2011. Bottom-up preparation techniques for nanocrystals of lipophilic drugs. Pharm. Res. 28, 1220-1223.
27. Diels, A.M.J., Michiels, C.W., 2006. High-pressure homogenization as a non-thermal technique for the inactivation of microorganisms. Crit. Rev. Microbiol. 32, 201-216. (Pubitemid 44851407)
28. Dolenc, A., Kristl, J., Baumgartner, S., Planinsek, O., 2009. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int. J. Pharm. 376, 204-212.
29. Du, S., Zhu, L., Du, B., Shi, X., Zhang, Z., Wang, S., Zhang, C., 2012. Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension. Drug Dev. Ind. Pharm. 38, 431-438.
30. Dumay, E., Chevalier-Lucia, D., Picart-Palmade, L., Benzaria, A., Gràcia-Julià, A., Blayo, C., 2012. Technological aspects and potential applications of (ultra) high-pressure homogenisation. Trends Food Sci. Technol., http://dx.doi.org/10.1016/j.tifs.2012.03.005.
31. EMA, 2004. Scientific Discussion Rapamune. EMA, London.
32. Fages, J., Lochard, H., Letourneau, J.-J., Sauceau, M., Rodier, E., 2004. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Technol. 141, 219-226. (Pubitemid 38726140)
33. Fichera, M.A., Keck, C.M., Müller, R.H., 2004. Nanopure Technology - Drug Nanocrystals for the Delivery of Poorly Soluble Drugs. Particles, Orlando.
34. Friesen, D.T., Shanker, R., Crew, M., Smithey, D.T., Curatolo, W.J., Nightingale, J.A.S., 2008. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol. Pharm. 5, 1003-1019.
35. Ganta, S., Paxton, J.W., Baguley, B.C., Garg, S., 2009. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int. J. Pharm. 367, 179-186.
36. Gao, L., Zhang, D., Chen, M., Duan, C., Dai, W., Jia, L., Zhao, W., 2008. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int. J. Pharm. 355, 321-327.
37. Gao, Y., Qian, S., Zhang, J., 2010. Physicochemical and pharmacokinetic characterization of a spray-dried cefpodoxime proxetil nanosuspension. Chem. Pharm. Bull. (Tokyo) 58, 912-917.
38. Ghosh, S., Chiang, P.C., Wahlstrom, J.L., Fujiwara, H., Selbo, J.G., Roberds, S.L., 2008. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin. Pharmacol. Toxicol. 102, 453-458. (Pubitemid 351537788)
39. Grau, M.J., Kayser, O., Müller, R.H., 2000. Nanosuspensions of poorly soluble drugs - reproducibility of small scale production. Int. J. Pharm. 196, 155-159. (Pubitemid 30105733)
40. Hecq, J., Deleers, M., Fanara, D., Vranckx, H., Amighi, K., 2005. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 299, 167-177. (Pubitemid 40962418)
41. Hecq, J., Deleers, M., Fanara, D., Vranckx, H., Boulanger, P., Le Lamer, S., Amighi, K., 2006. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur. J. Pharm. Biopharm. 64, 360-368. (Pubitemid 44585201)
42. Heng, D., Ogawa, K., Cutler, D.J., Chan, H.-K., Raper, J.A., Ye, L., Yun, J., 2009. Pure drug nanoparticles in tablets: what are the dissolution limitations? J. Nanopart. Res. 12, 1743-1754.
43. Hennart, S.L.A., Domingues, M.C., Wildeboer, W.J., van Hee, P., Meesters, G.M.H., 2010. Study of the process of stirred ball milling of poorly water soluble organic products using factorial design. Powder Technol. 198, 56-60.
44. Hennart, S.L.A., van Hee, P., Drouet, V., Domingues, M.C., Wildeboer, W.J., Meesters, G.M.H., 2012. Characterization and modeling of a sub-micron milling process limited by agglomeration phenomena. Chem. Eng. Sci. 71, 484-495.
45. Hu, J., Johnston, K.P., Williams 3rd, R.O., 2003. Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur. J. Pharm. Sci. 20, 295-303. (Pubitemid 37338535)
46. Innings, F., Hultman, E., Forsberg, F., Prakash, B., 2011. Understanding and analysis of wear in homogenizers for processing liquid food. Wear 271, 2588-2598.
47. Jacobs, C., Kayser, O., Müller, R.H., 2000. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int. J. Pharm. 196, 161-164. (Pubitemid 30105734)
48. Jacobs, C., Kayser, O., Müller, R.H., 2001. Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int. J. Pharm. 214, 3-7. (Pubitemid 32244068)
49. Jacobs, C., Müller, R.H., 2002. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 19, 189-194. (Pubitemid 34165405)
50. Jia, L., Wong, H., Wang, Y., Garza, M., Weitman, S.D., 2003. Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle. J. Pharm. Sci. 92, 161-172. (Pubitemid 36042307)
51. Jinno, J., Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G.G., Higaki, K., Kimura, T., 2006. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 111, 56-64. (Pubitemid 43289995)
52. Jinno, J., Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G.G., Higaki, K., Kimura, T., 2008. In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J. Control. Release 130, 29-37.
53. Juhnke, M., Berghausen, J., Timpe, C., 2010. Accelerated formulation development for nanomilled active pharmaceutical ingredients using a screening approach. Chem. Eng. Technol. 33, 1412-1418.
54. Juhnke, M., Martin, D., John, E., 2012. Generation of wear during the production of drug nanosuspensions by wet media milling. Eur. J. Pharm. Biopharm.
55. Junghanns, J.U., Müller, R.H., 2008. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed. 3, 295-309.
56. Kassem, M.A., Abdel Rahman, A.A., Ghorab, M.M., Ahmed, M.B., Khalil, R.M., 2007. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 340, 126-133. (Pubitemid 47043351)
57. Kayaert, P., Anne, M., Van den Mooter, G., 2011. Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in vitro release from sugar beads. J. Pharm. Pharmacol. 63, 1446-1453.
58. Kayser, O., Olbrich, C., Yardley, V., Kiderlen, A.F., Croft, S.L., 2003. Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 254, 73-75. (Pubitemid 36259814)
59. Keck, C.M., Müller, R.H., 2006. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 62, 3-16. (Pubitemid 41736019)
60. Kesisoglou, F., Panmai, S., Wu, Y., 2007. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59, 631-644. (Pubitemid 47285408)
61. Kesisoglou, F., Wu, Y., 2008. Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J. 10, 516-525.
62. Kipp, J.E., 2004. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 284, 109-122. (Pubitemid 39349144)
63. Kipp, J.E., Wong, J.C.T., Doty, M.J., Rebbeck, C.L., 2003. Microprecipitation Method for Preparing Submicron Suspensions, United States Patent 6,607,784. Baxter International Inc., Deerfield, IL, USA.
64. Kluge, J., Muhrer, G., Mazzotti, M., 2012. High pressure homogenization of pharmaceutical solids. J. Supercrit. Fluids 66, 380-388.
65. Kobierski, S., Ofori-Kwakye, K., Müller, R.H., Keck, C.M., 2009. Resveratrol nanosuspensions for dermal application - production, characterization, and physical stability. Pharmazie 64, 741-747.
66. Krause, K.P., Kayser, O., Mader, K., Gust, R., Müller, R.H., 2000. Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation. Int. J. Pharm. 196, 169-172. (Pubitemid 30105736)
67. Ku, M.S., 2008. Use of the biopharmaceutical classification system in early drug development. AAPS J. 10, 208-212.
68. Ku, M.S., Dulin, W., 2012. A biopharmaceutical classification-based right-first-time formulation approach to reduce human pharmacokinetic variability and project cycle time from first-in-human to clinical proof-of-concept. Pharm. Dev. Technol. 17, 285-302.
69. Kwade, A., 1999a. Determination of the most important grinding mechanism in stirred media mills by calculating stress intensity and stress number. Powder Technol. 105, 382-388. (Pubitemid 29531638)
70. Kwade, A., 1999b. Wet comminution in stirred media mills - research and its practical application. Powder Technol. 105, 14-20. (Pubitemid 29531589)
71. Kwong, E., Higgins, J., Templeton, A.C., 2011. Strategies for bringing drug delivery tools into discovery. Int. J. Pharm. 412, 1-7.
72. Lai, F., Sinico, C., Ennas, G., Marongiu, F., Marongiu, G., Fadda, A.M., 2009. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour. Int. J. Pharm. 373, 124-132.
73. Langguth, P., Hanafy, A., Frenzel, D., Grenier, P., Nhamias, A., Ohlig, T., Vergnault, G., Spahn-Langguth, H., 2005. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev. Ind. Pharm. 31, 319-329. (Pubitemid 40463975)
74. Lee, J., 2003. Drug nano- and microparticles processed into solid dosage forms: physical properties. J. Pharm. Sci. 92, 2057-2068. (Pubitemid 37175635)
75. Lenhardt, T., Vergnault, G., Grenier, P., Scherer, D., Langguth, P., 2008. Evaluation of nanosuspensions for absorption enhancement of poorly soluble drugs: in vitro transport studies across intestinal epithelial monolayers. AAPS J. 10, 435-438.
76. Leuner, C., Dressman, J., 2000. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50, 47-60. (Pubitemid 30326688)
77. Levoguer, C., 2012. Trends in particle characterisation tools. Innov. Pharm. Technol., 74-77.
78. Li, P., Zhao, L., 2007. Developing early formulations: practice and perspective. Int. J. Pharm. 341, 1-19. (Pubitemid 47088122)
79. Li, S., Doyle, P., Metz, S., Royce, A.E., Serajuddin, A.T.M., 2005. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug. J. Pharm. Sci. 94, 2224-2231. (Pubitemid 41665282)
80. Li, W., Yang, Y., Tian, Y., Xu, X., Chen, Y., Mu, L., Zhang, Y., Fang, L., 2011. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int. J. Pharm. 408, 157-162.
81. Liversidge, G.G., 2011. Recent trends in drug discovery & drug solubility: a novel hybrid particle-engineering approach to solving the insoluble. Drug Dev. Deliv. 11, 42-45.
82. Liversidge, G.G., Conzentino, P., 1995. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125, 309-313.
83. Liversidge, G.G., Cundy, K.C., Bishop, J.F., Czekai, D.A., 1992. Surface Modified Drug Nanoparticles, United States Patent 5,145,684. Sterling Drug Inc., New York, NY, USA.
84. Maas, J., Kamm, W., Hauck, G., 2007. An integrated early formulation strategy - from hit evaluation to preclinical candidate profiling. Eur. J. Pharm. Biopharm. 66, 1-10. (Pubitemid 46412973)
85. Maston, D.W., Fulton, J.L., Petersen, R.C., Smith, R.D., 1987. Rapid expansion of supercritical solutions: solute formation of powders, thin film, and fibers. Ind. Eng. Chem. Res. 26, 2298-2306.
86. Mauludin, R., Müller, R.H., Keck, C.M., 2009. Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur. J. Pharm. Sci. 36, 502-510.
87. Merisko-Liversidge, E., Liversidge, G.G., 2011. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv. Drug Deliv. Rev. 63, 427-440.
88. Merisko-Liversidge, E., Liversidge, G.G., Cooper, E.R., 2003. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18, 113-120. (Pubitemid 36184748)
89. Merisko-Liversidge, E., Sarpotdar, P., Bruno, J., Hajj, S., Wei, L., Peltier, N., Rake, J., Shaw, J.M., Pugh, S., Polin, L., Jones, J., Corbett, T., Cooper, E., Liversidge, G.G., 1996. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 13, 272-278. (Pubitemid 26074194)
90. Merisko-Liversidge, E.M., Liversidge, G.G., 2008. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 36, 43-48.
91. Mishra, A.K., Achon, M.G., Guivarch, P., Snow, R.S., Pace, G.W., 2003. IDD technology: oral delivery of water-insoluble drugs using phospholipid-stabilized microparticulate IDD formulations. In: Rathbone, M.J., Hadgraft, J., Roberts, M.S. (Eds.), Modified-Release Drug Delivery Technology. Marcel Dekker, New York, pp. 151-175.
92. Mishra, P.R., Al Shaal, L., Müller, R.H., Keck, C.M., 2009. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int. J. Pharm. 371, 182-189.
93. Möschwitzer, J., 2005. Method for Producing Ultrafine Submicronic Suspensions, US000008034381B2, Germany.
94. Möschwitzer, J., Achleitner, G., Pomper, H., Müller, R.H., 2004. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. 58, 615-619. (Pubitemid 39297108)
95. Möschwitzer, J., Lemke, A., 2005. Method for carefully producing ultrafine particle suspensions and ultrafine particles and use thereof, EP000001868574B1.
96. Möschwitzer, J., Müller, R.H., 2006a. New method for the effective production of ultrafine drug nanocrystals. J. Nanosci. Nanotechnol. 6, 3145-3153. (Pubitemid 44579994)
97. Möschwitzer, J., Müller, R.H., 2006b. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur. J. Pharm. Biopharm. 62, 282-287. (Pubitemid 43356577)
98. Möschwitzer, J.M., Rainer, H., 2011. Nanocrystal formulations for improved delivery of poorly soluble drugs. In: Hunter, R.J., Preedy, V.R. (Eds.), Nanomedicines in Health and Diseases. CRC Press, Taylor and Francis.
99. Möschwitzer, J.P., Op't Land, H., 2008. Early formulation - shortening the development timelines. Pharma Focus Asia, 38-42.
100. Müller, R.H., Böhm, B.H.L., 1998. Nanosuspensions. In: Müller, R.H., Benita, S., Böhm, B. (Eds.), Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. Medpharm Scientific Publishers, Stuttgart, pp. 149-174.
101. Müller, R.H., Jacobs, C., Kayser, O., 2003. DissoCubes - a novel formulation for poorly soluble and poorly bioavailable drugs. In: Rathbone, M.J., Hadgraft, J., Roberts, M.S. (Eds.), Modified-Release Drug Delivery Technology. Marcel Dekker, pp. 135-149.
102. Müller, R.H., Keck, C.M., 2012. Twenty years of drug nanocrystals: where are we, and where do we go? Eur. J. Pharm. Biopharm. 80, 1-3.
103. Müller, R.H., Mader, K., Gohla, S., 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161-177. (Pubitemid 30326695)
104. Müller, R.H., Möschwitzer, J., 2005. Method and Device for Producing Very Fine Particles and Coating Such Particles, WO002007051520A3, Germany.
105. Müller, R.H., Peters, K., 1998. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int. J. Pharm. 160, 229-237. (Pubitemid 28083096)
106. Müller, R.H., Radtke, M., Wissing, S.A., 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54, S131L 155.
107. Müller, R.H., Shegokar, R., Keck, C.M., 2011. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol. 8, 207-227.
108. Müller, R.H.B., Robert, K., Bernd, P.K. Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit. dds drug delivery services Gesellschaft zur Förderung der Forschung in pharmazeutischer Technologie und Biopharmazie mbH.
109. Müller, R.H.K., Karsten, M.K. Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln. PharmaSol GmbH.
110. Na, G.C., Stevens Jr., H.J., Yuan, B.O., Rajagopalan, N., 1999. Physical stability of ethyl diatrizoate nanocrystalline suspension in steam sterilization. Pharm. Res. 16, 569-574. (Pubitemid 29191304)
111. Nakarani, M., Patel, P., Patel, J., Murthy, R.S., Vaghani, S.S., 2010. Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation. Sci. Pharm. 78, 345-361.
112. Nekkanti, V., Pillai, R., Venkateshwarlu, V., Harisudhan, T., 2009. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Pharm. Dev. Technol. 14, 290-298.
113. Pardeike, J., Müller, R.H., 2010. Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18. Int. J. Pharm. 391, 322-329.
114. Peters, K., Leitzke, S., Diederichs, J.E., Borner, K., Hahn, H., Müller, R.H., Ehlers, S., 2000. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 45, 77-83. (Pubitemid 30060237)
115. Pouton, C.W., 2006. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 29, 278-287. (Pubitemid 44740131)
116. Quan, P., Xia, D., Piao, H., Shi, K., Jia, Y., Cui, F., 2011. Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation. AAPS Pharm-SciTech 12, 1136-1143.
117. Rabinow, B., Kipp, J., Papadopoulos, P., Wong, J., Glosson, J., Gass, J., Sun, C.S., Wielgos, T., White, R., Cook, C., Barker, K., Wood, K., 2007. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int. J. Pharm. 339, 251-260. (Pubitemid 46977603)
118. Rabinow, B.E., 2004. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3, 785-796. (Pubitemid 39242830)
119. Radtke, M., 2001. Nanopure™ pure drug nanoparticles for the formulation of porly soluble drugs. New Drugs 3, 62-68.
120. Rao, S., Song, Y., Peddie, F., Evans, A.M., 2011. Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs. Int. J. Nanomed. 6, 1245-1251.
121. Rasenack, N., Müller, B.W., 2002a. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm. Res. 19, 1894-1900. (Pubitemid 36016039)
122. Rasenack, N., Müller, B.W., 2002b. Ibuprofen crystals with optimized properties. Int. J. Pharm. 245, 9-24. (Pubitemid 35299887)
123. Salazar, J., 2012. Combinative particle size reduction technologies for the formulation of poorly soluble drugs, PhD thesis in preparation, Freie Universität Berlin, Berlin.
124. Salazar, J., Ghanem, A., Müller, R.H., Möschwitzer, J.P., 2012. Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches. Eur. J. Pharm. Biopharm. 81, 82-90.
125. Salazar, J., Heinzerling, O., Müller, R.H., Möschwitzer, J.P., 2011. Process optimization of a novel production method for nanosuspensions using design of experiments (DoE). Int. J. Pharm. 420, 395-403.
126. Sauron, R., Wilkins, M., Jessent, V., Dubois, A., Maillot, C., Weil, A., 2006. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int. J. Clin. Pharmacol. Ther. 44, 64-70. (Pubitemid 43230588)
127. Schultheiss, N., Newman, A., 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst. Growth Des. 9, 2950-2967.
128. Serajuddin, A.T.M., 2007. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 59, 603-616. (Pubitemid 47285406)
129. Sharma, P., Denny, W.A., Garg, S., 2009. Effect of wet milling process on the solid state of indomethacin and simvastatin. Int. J. Pharm. 380, 40-48.
130. Sharma, P., Zujovic, Z.D., Bowmaker, G.A., Marshall, A.J., Denny, W.A., Garg, S., 2011. Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies. Int. J. Pharm. 408, 138-151.
131. Shegokar, R., Müller, R.H., 2010. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int. J. Pharm. 399, 129-139.
132. Shi, Y., Porter, W., Merdan, T., Li, L.C., 2009. Recent advances in intravenous delivery of poorly water-soluble compounds. Expert Opin. Drug Deliv. 6, 1261-1282.
133. Shono, Y., Jantratid, E., Kesisoglou, F., Reppas, C., Dressman, J.B., 2010. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur. J. Pharm. Biopharm. 76, 95-104.
134. Shrewsbury, S.B., Bosco, A.P., Uster, P.S., 2009. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int. J. Pharm. 365, 12-17.
135. Sigfridsson, K., Lundqvist, A., Strimfors, M., 2011a. Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor - the importance of gastrointestinal pH and solubility for the in vivo exposure. Drug Dev. Ind. Pharm. 37, 1036-1042.
136. Sigfridsson, K., Lundqvist, A.J., Strimfors, M., 2009. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev. Ind. Pharm. 35, 1479-1486.
137. Sigfridsson, K., Lundqvist, A.J., Strimfors, M., 2011b. Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev. Ind. Pharm. 37, 243-251.
138. Sigfridsson, K., Nordmark, A., Theilig, S., Lindahl, A., 2011c. A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Dev. Ind. Pharm. 37, 185-192.
139. Staedtke, V., Brahler, M., Müller, A., Georgieva, R., Bauer, S., Sternberg, N., Voigt, A., Lemke, A., Keck, C., Möschwitzer, J., Baumler, H., 2010. In vitro inhibition of fungal activity by macrophage-mediated sequestration and release of encapsulated amphotericin B nanosupension in red blood cells. Small 6, 96-103.
140. Steckel, H., Rasenack, N., Villax, P., Müller, B.W., 2003. In vitro characterization of jet-milled and in situ-micronized fluticasone-17-propionate. Int. J. Pharm. 258, 65-75. (Pubitemid 36712871)
141. Strickley, R.G., 2004. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21, 201-230. (Pubitemid 38221966)
142. Sucker, H., 1998. Hydrosole, eine Alternative für die parenterale Anwendung von schwer wasserlöslichen Wirkstoffen. In: Müller, R.H., Hildebrand, G.E. (Eds.), Pharmazeutische Technologie: Moderne Arzneiformen. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, pp. 383-391.
143. Teeranachaideekul, V., Junyaprasert, V.B., Souto, E.B., Müller, R.H., 2008. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int. J. Pharm. 354, 227-234.
144. Van Eerdenbrugh, B., Froyen, L., Martens, J.A., Blaton, N., Augustijns, P., Brewster, M., Van den Mooter, G., 2007. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int. J. Pharm. 338, 198-206. (Pubitemid 46779149)
145. Van Eerdenbrugh, B., Froyen, L., Van Humbeeck, J., Martens, J.A., Augustijns, P., Van den Mooter, G., 2008. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur. J. Pharm. Sci. 35, 127-135.
146. Van Eerdenbrugh, B., Stuyven, B., Froyen, L., Van Humbeeck, J., Martens, J.A., Augustijns, P., Van den Mooter, G., 2009a. Downscaling drug nanosuspension production: processing aspects and physicochemical characterization. AAPS PharmSciTech 10, 44-53.
147. Van Eerdenbrugh, B., Vermant, J., Martens, J.A., Froyen, L., Humbeeck, J.V., Van den Mooter, G., Augustijns, P., 2010. Solubility increases associated with crystalline drug nanoparticles: methodologies and significance. Mol. Pharm. 7, 1858-1870.
148. Van Eerdenbrugh, B., Vermant, J., Martens, J.A., Froyen, L., Van Humbeeck, J., Augustijns, P., Van den Mooter, G., 2009b. A screening study of surface stabilization during the production of drug nanocrystals. J. Pharm. Sci. 98, 2091-2103.
149. Wang, Y., Li, X., Wang, L., Xu, Y., Cheng, X., Wei, P., 2011. Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. Int. J. Nanomed. 6, 1497-1507.
150. Wang, P., Luo, Q., Miao, Y., Ying, L., He, H., Cai, C., Tang, X., 2012. Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. Drug Dev. Ind. Pharm. 38, 1344-1353.
151. Willmann, S., Thelen, K., Becker, C., Dressman, J.B., Lippert, J., 2010. Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. Eur. J. Pharm. Biopharm. 76, 83-94.
152. Wong, J., Brugger, A., Khare, A., Chaubal, M., Papadopoulos, P., Rabinow, B., Kipp, J., Ning, J., 2008. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Drug Deliv. Rev. 60, 939-954.
153. Wu, L., Zhang, J., Watanabe, W., 2011. Physical and chemical stability of drug nanoparticles. Adv. Drug Deliv. Rev. 63, 456-469.
154. Wu, Y., Loper, A., Landis, E., Hettrick, L., Novak, L., Lynn, K., Chen, C., Thompson, K., Higgins, R., Batra, U., Shelukar, S., Kwei, G., Storey, D., 2004. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285, 135-146. (Pubitemid 39361543)
155. Xia, D., Cui, F., Piao, H., Cun, D., Jiang, Y., Ouyang, M., Quan, P., 2010. Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. Pharm. Res. 27, 1965-1976.
156. Xiong, R., Lu, W., Li, J., Wang, P., Xu, R., Chen, T., 2008. Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int. J. Pharm. 350, 338-343.
157. York, P., 1999. Strategies for particle design using supercritical fluid technologies. Pharm. Sci. Technol. Today 2, 430-440. (Pubitemid 29528142)
158. Yu, Z., Garcia, A.S., Johnston, K.P., Williams 3rd, R.O., 2004. Spray freezing into liquid nitrogen for highly stable protein nanostructured microparticles. Eur. J. Pharm. Biopharm. 58, 529-537. (Pubitemid 39297099)
159. Zhang, D., Tan, T., Gao, L., Zhao, W., Wang, P., 2007. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev. Ind. Pharm. 33, 569-575. (Pubitemid 46808766)
160. Zhang, Z., Zhang, X., Xue, W., Yangyang, Y., Xu, D., Zhao, Y., Lou, H., 2010. Effects of oridonin nanosuspension on cell proliferation and apoptosis of human prostatic carcinoma PC-3 cell line. Int. J. Nanomed. 5, 735-742.
161. Zheng, J.Y., Bosch, H.W., 1997. Sterile filtration of NanoCrystal™ drug formulations. Drug Dev. Ind. Pharm. 23, 1087-1093. (Pubitemid 27454098)
162. Zhu, T., Ansquer, J.C., Kelly, M.T., Sleep, D.J., Pradhan, R.S., 2010. Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. J. Clin. Pharmacol. 50, 914-921.